Crystalline forms of an androgen receptor modulator

Patent metadata

Field	Value
Publication number	US-10556882-B2
Application number	US-201916507780-A
Country	US
Kind code	B2
Filing date	Jul 10, 2019
Priority date	Jun 7, 2012
Publication date	Feb 11, 2020
Grant date	Feb 11, 2020

Abstract

Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.

First claim

What is claimed is:

1. A crystalline Form H of 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide that exhibits an an X-ray powder diffraction (XRPD) pattern with characteristic peaks at 8.0±0.1°2-Theta, 14.7±0.1°2-Theta, 15.9±0.1°2-Theta, 18.2±0.1°2-Theta, 25.7±0.1°2-Theta, and 26.7±0.1°2-Theta.

2. The crystalline Form H of claim 1 that is further characterized as exhibiting at least one of:
(a) an X-Ray powder diffraction (XRPD) pattern as set forth in FIG. 8 ;
(b) a DSC thermogram substantially as set forth in FIG. 17 ;
(c) a DSC thermogram with a first endotherm having an onset temperature at about 173° C. and second endotherm having an onset temperature at about 193° C.; or
(d) substantially the same X-ray powder diffraction (XRPD) pattern as post storage at 40° C. and 75% RH for at least a week.

3. The crystalline Form H of claim 1 that is further characterized as exhibiting a DSC thermogram with a first endotherm having an onset temperature at about 173° C.

4. The crystalline Form H of claim 1 , wherein the crystalline form is unsolvated.

5. A pharmaceutical composition comprising 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide and at least one additional ingredient that is a pharmaceutically acceptable carrier, diluent, or excipient, in which the 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide in the composition comprises the crystalline Form H according to claim 1 .

6. The pharmaceutical composition according to claim 5 , wherein the pharmaceutical composition is in a form formulated for oral administration to a mammal.

7. The pharmaceutical composition of claim 6 , wherein the mammal is a human.

8. The pharmaceutical composition according to claim 5 , wherein the pharmaceutical composition is in an oral solid dosage form.

9. The pharmaceutical composition according to claim 5 , wherein the pharmaceutical composition comprises about 0.5 mg to about 1000 mg of the crystalline Form H of 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-cliazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.

10. A method of treating prostate cancer in a mammal comprising administering the crystalline Form H of 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide according to claim 1 to the mammal in need of such treatment.

11. A method of treating prostate cancer in a mammal comprising administering the pharmaceutical composition according to claim 5 to the mammal in need of such treatment.

12. The method of claim 10 , wherein the prostate cancer is hormone sensitive prostate cancer or hormone refractory prostate cancer.

13. The method of claim 11 , wherein the prostate cancer is hormone sensitive prostate cancer or hormone refractory prostate cancer.

14. The method of claim 10 , wherein the mammal is a human.

15. The method of claim 11 , wherein the mammal is a human.

16. The method of claim 12 , wherein the mammal is a human.

17. The method of claim 13 , wherein the mammal is a human.

18. The crystalline Form H of claim 1 that is further characterized as exhibiting an X-Ray powder diffraction (XRPD) pattern as set forth in FIG. 8 .

19. The crystalline Form H of claim 1 that is further characterized as exhibiting a DSC thermogram as set forth in FIG. 17 .

Assignees

• Aragon Pharmaceuticals Inc
• Sloan Kettering Inst Cancer Res

Inventors

• Dilhas Anna
• Herbert Mark R
• Ouerfelli Ouathek
• Smith Nicholas D

Classifications

• A61P5/28

  Antiandrogens · CPC title

• A61P5/00

  Drugs for disorders of the endocrine system · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P33/00

  Antiparasitic agents · CPC title

• A61P15/00

  Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives · CPC title